<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316469</url>
  </required_header>
  <id_info>
    <org_study_id>Narges Essam protocol 2017</org_study_id>
    <nct_id>NCT03316469</nct_id>
  </id_info>
  <brief_title>Anti-Mullerian Hormone as Predictor of Ovarian Responce to Clomiphene Citrate in PCOS</brief_title>
  <official_title>Circulating Anti-mullerian Hormone as Predictor of Ovarian Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is found in 5% to 6% of women of reproductive age. It
      affects women's reproductive capability; thus patients have risks of infertility,
      miscarriage, and complicated pregnancy. A study revealed that the prevalence of
      oligoovulation or anovulation in patients with PCOS ranged from 65% to 80%. Anti-Mullerian
      Hormone (AMH) is an important regulator in the ovary that play a rule during development and
      function. It is suspected to affect clomiphene citrate (cc) resistance. In this study the
      investigator will assess the accuracy of AMH prediction of response to cc in women with PCOS.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AMH in prediction of Ovulation in women with PCOS.</measure>
    <time_frame>10 days</time_frame>
    <description>AMH level is measured 10 days before expected date of ovulation then correlated to ovulation either successfully or not.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Group A: CC &amp; ovulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMH level is measured before Clomiphene citrate 100 mg daily for 5 days &amp; detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: CC &amp; no ovulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMH level is measured before Clomiphene citrate 100 mg daily for 5 days &amp; detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene Citrate</intervention_name>
    <description>100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods</description>
    <arm_group_label>Group A: CC &amp; ovulation</arm_group_label>
    <arm_group_label>Group B: CC &amp; no ovulation</arm_group_label>
    <other_name>Clomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Follicular growth</intervention_name>
    <description>Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.</description>
    <arm_group_label>Group A: CC &amp; ovulation</arm_group_label>
    <arm_group_label>Group B: CC &amp; no ovulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women diagnosed with PCOS

          -  Women 20-35 years old.

          -  BMI ≤30 kg/m without previous ovulation induction.

          -  Partners with normal semen parameters Parameter World Health Organization (WHO) 2010
             Volume1.5 ml Concentration 15 million/ml Progressive motility 32% Normal forms 4%

        Exclusion Criteria:

          -  Women with evidence of hyper-or hypothyroidism, hyperprolactinemia, Cushing's
             syndrome, congenital adrenal hyperplasia or androgen-secreting tumors.

          -  Women with factors of infertility other than PCOS

          -  Women with incomplete data.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006 Mar;91(3):781-5. Epub 2006 Jan 17.</citation>
    <PMID>16418211</PMID>
  </reference>
  <reference>
    <citation>Catteau-Jonard S, Pigny P, Reyss AC, Decanter C, Poncelet E, Dewailly D. Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome. J Clin Endocrinol Metab. 2007 Nov;92(11):4138-43. Epub 2007 Aug 14.</citation>
    <PMID>17698904</PMID>
  </reference>
  <reference>
    <citation>Dumesic DA, Lesnick TG, Stassart JP, Ball GD, Wong A, Abbott DH. Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertilization and embryo transfer. Fertil Steril. 2009 Jul;92(1):217-21. doi: 10.1016/j.fertnstert.2008.04.047.</citation>
    <PMID>18675414</PMID>
  </reference>
  <reference>
    <citation>Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod. 2003 Nov;18(11):2357-62.</citation>
    <PMID>14585887</PMID>
  </reference>
  <reference>
    <citation>Hart R, Norman R. Polycystic ovarian syndrome--prognosis and outcomes. Best Pract Res Clin Obstet Gynaecol. 2006 Oct;20(5):751-78. Epub 2006 Jun 12. Review.</citation>
    <PMID>16766228</PMID>
  </reference>
  <reference>
    <citation>Ghobadi C, Nguyen TH, Lennard MS, Amer S, Rostami-Hodjegan A, Ledger WL. Evaluation of an existing nomogram for predicting the response to clomiphene citrate. Fertil Steril. 2007 Mar;87(3):597-602. Epub 2006 Dec 6.</citation>
    <PMID>17156783</PMID>
  </reference>
  <reference>
    <citation>Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998 Jul;83(7):2361-5.</citation>
    <PMID>9661609</PMID>
  </reference>
  <reference>
    <citation>Kurabayashi T, Suzuki M, Fujita K, Murakawa H, Hasegawa I, Tanaka K. Prognostic factors for ovulatory response with clomiphene citrate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):201-5. Epub 2005 Dec 7.</citation>
    <PMID>16337728</PMID>
  </reference>
  <reference>
    <citation>Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004 Jan;89(1):318-23.</citation>
    <PMID>14715867</PMID>
  </reference>
  <reference>
    <citation>Mashiach R, Amit A, Hasson J, Amzalzg S, Almog B, Ben-Yosef D, Lessing JB, Limor R, Azem F. Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome. Fertil Steril. 2010 May 1;93(7):2299-302. doi: 10.1016/j.fertnstert.2009.01.125. Epub 2009 Mar 3.</citation>
    <PMID>19261276</PMID>
  </reference>
  <reference>
    <citation>Messinis IE. Ovulation induction: a mini review. Hum Reprod. 2005 Oct;20(10):2688-97. Epub 2005 Jul 8. Review.</citation>
    <PMID>16006478</PMID>
  </reference>
  <reference>
    <citation>Hintze, J. (2011). PASS 11. NCSS, LLC. Kaysville, Utah, USA.</citation>
  </reference>
  <reference>
    <citation>Balen A. Ovulation induction. Obstet Gynaecol Reprod Med. 2004;14:261-268.</citation>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Narges Essam El-din Marrey</investigator_full_name>
    <investigator_title>Resident of obs &amp; gyn.</investigator_title>
  </responsible_party>
  <keyword>Anti-mullerian hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

